Shashi Shankar: Understanding Barriers to Biomarker Testing is a Bold Step Towards Equity in Care
Aakash Desai, Associate Director and Assistant Professor at UAB O’Neal Comprehensive Cancer Center, reshared the post by Shashi Shankar, Co-Founder & CEO of Novellia, on LinkedIn, adding:
“The powerful message here about moving beyond fragmented data to uncover complete patient stories resonates deeply with me. As someone who has navigated the clinical and innovation landscapes, I’ve seen first hand how vital it is to close the gaps that traditional systems often overlook.
The partnership between Novellia and the UAB O’Neal Comprehensive Cancer Center to understand barriers to biomarker testing is a bold step toward equity in care – where no patient’s zip code dictates their access to life-saving interventions.
If there’s one thing I’ve learned, it’s that the future of healthcare relies on aligning expertise, technology, and human-centered approaches to create meaningful impact.
As we work together to build solutions that save time and hopefully lives, I am excited to lend my perspective to endeavors like these – bridging clinical expertise with strategic insight to amplify change.
Quoting Shashi Shankar‘s post:
“Healthcare isn’t just about collecting data points – it’s about seeing the complete story. The warning signs before a diagnosis. Identifying treatment patterns that work and those that don’t. Closing hidden gaps to save more lives.
The problem is most traditional data solutions still just tell a small slice of the story, and there’s not a whole heck of a lot doctors and life science researchers can do with that tiny sliver.
That’s why last week’s visit to see the brilliant minds at the UAB O’Neal Comprehensive Cancer Center hit different. When one of the country’s leading NCI-designated comprehensive cancer centers partners up with you to transform NSCLC detection and treatment… you know you’re onto something.
Earlier this year, our research on disparities in NSCLC biomarker testing was recognized by ASCO. Now, with support from the visionary team at Daiichi Sankyo US, we’re diving deeper into how we can level the playing field in cancer care. Novellia’s platform – which integrates across tens of thousands of data sources across the US and seamlessly unifies messy health data spanning years of each patient’s life to paint complete stories– is helping life science companies and researchers spot and close critical gaps far faster than traditional methods.
But to us…this isn’t just about efficiency. It’s about equity. About ensuring your zip code doesn’t determine your access. About giving every family more time together.
Big moves coming from this partnership. We’re working on something truly extraordinary, and I can’t wait to see where we go in 2025.
Because helping the world say goodbye to early goodbyes isn’t just our mission – it’s personal.”
Here’s to transforming not just healthcare but lives. Let’s make 2025 extraordinary!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023